Javier Pascual

Biografía y Trayectoria

Javier Pascual MD holds a Doctor of Medicine from The Institute of Cancer Research at the University of London (2021).

He is a clinician-scientist who combines clinical activities mainly leading clinical trials for breast cancer at his institution and translational research mainly in the field of new prognostic and predictive biomarkers to novel therapies, with special dedication to the use of liquid biopsy technologies in breast cancer.

He currently serves as Medical Oncologist and Clinical Trial Coordinator in the Breast Unit at Hospital Universitario Virgen de la Victoria (Málaga, Spain), Principal Investigator of the Translational Liquid Biopsy Laboratory at the Biomedical Research Institute of Málaga (IBIMA) and Scientific Director of the Molecular Biology Laboratory within CIMES. He is current or past member of some national and international scientific organizations in the field such as the Spanish Society of Medical Oncology (SEOM), the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), the Spanish Breast Cancer Group (GEICAM) Board of Directors, the European Organisation for Research and Treatment of Cancer (EORTC) and the Oncology Biomedical Research National Network (CIBERONC Breast Cancer CB16/12/00481).

Dr. Pascual has extensive experience in liquid biopsy technologies, partially in technical aspects including Digital PCR and Next-Generation Sequencing hands-on experience but fundamentally in the design of research strategies to develop potential clinical utilities that may arise from implementation of the technology for clinical decision making. Specifically, he is actively involved in the development of new strategies for early cancer detection and the use of early circulating tumor DNA dynamics for treatment efficacy predictions.

He has served as Principal Investigator at his institution for 20 clinical trials, and Sub Investigator for more than other 25. and has authored or co-authored many scientific articles in some of the highest impact factor journals including The New England Journal of Medicine, Annals of Oncology, Cancer Discovery, Nature Cancer and Clinical Cancer Research, among others, including lead authorship of the most recent international recommendations for the use of liquid biopsies to treat patients with cancer.

Líneas de Investigación Actuales

• Optimización de protocolos de aislamiento de ctDNA.
• Evaluación del valor pronóstico de las Células Tumorales Circulantes (CTCs).
• Desarrollo de paneles de secuenciación de nueva generación (NGS) adaptados a la biopsia líquida.
• Estudio de microvesículas y exosomas en la metástasis tumoral.

Publicaciones Destacadas

Puede consultar el listado completo en el perfil ORCID.

El Dr. Toledo ha publicado más de 50 artículos en revistas peer-reviewed, incluyendo *JAMA Oncology* y *Clinical Cancer Research*. Es revisor habitual de diversas revistas científicas internacionales y participa activamente en congresos internacionales.